

DAFTAR PUSTAKA

- Adan, A., Kiraz, Y., & Baran, Y. (2016). Cell Proliferation and Cytotoxicity Assays. *Current Pharmaceutical Biotechnology*, 17(14), 1213–1221. <https://doi.org/10.2174/1389201017666160808160513>
- Ahn, S., Woo, J. W., Lee, K., & Park, S. Y. (2020). HER2 status in breast cancer: Changes in guidelines and complicating factors for interpretation. *Journal of Pathology and Translational Medicine*, 54(1), 34–44. <https://doi.org/10.4132/jptm.2019.11.03>
- Amberger, J. S., Bocchini, C. A., Scott, A. F., & Hamosh, A. (2019). OMIM.org: Leveraging knowledge across phenotype–gene relationships. *Nucleic Acids Research*, 47(D1), D1038–D1043. <https://doi.org/10.1093/nar/gky1151>
- Bansod, S., Chilvery, S., Saifi, M. A., Das, T. J., Tag, H., & Godugu, C. (2021). Borneol protects against cerulein-induced oxidative stress and inflammation in acute pancreatitis mice model. *Environmental Toxicology*, 36(4), 530–539. <https://doi.org/10.1002/tox.23058>
- Boekhout, A. H., Beijnen, J. H., & Schellens, J. H. M. (2011). Trastuzumab. *The Oncologist*, 16(6), 800–810. <https://doi.org/10.1634/theoncologist.2010-0035>
- Campbell, K. J., & Tait, S. W. G. (2018). Targeting BCL-2 regulated apoptosis in cancer. *Open Biology*, 8(5), 180002. <https://doi.org/10.1098/rsob.180002>
- Cao, W., Li, Y., Hou, Y., Yang, M., Fu, X., Zhao, B., Jiang, H., & Fu, X. (2019). Enhanced anticancer efficiency of doxorubicin against human glioma by natural borneol through triggering ROS-mediated signal. *Biomedicine & Pharmacotherapy*, 118, 109261. <https://doi.org/10.1016/j.biopha.2019.109261>
- Cao, W., Zhai, X., Ma, J., Fu, X., Zhao, B., Zhang, P., & Fu, X. (2020). Natural borneol sensitizes human glioma cells to cisplatin-induced apoptosis by triggering ROS-mediated oxidative damage and regulation of MAPKs and PI3K/AKT pathway. *Pharmaceutical Biology*, 58(1), 72–79. <https://doi.org/10.1080/13880209.2019.1703756>
- Capper, C. P., Larios, J. M., Sikora, M. J., Johnson, M. D., & Rae, J. M. (2016). The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. *Breast Cancer Research and Treatment*, 157(1), 23–30. <https://doi.org/10.1007/s10549-016-3774-3>
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., Antipin, Y., Reva, B., Goldberg, A. P., Sander, C., & Schultz, N. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. *Cancer Discovery*, 2(5), 401–404. <https://doi.org/10.1158/2159-8290.CD-12-0095>

- Chandarlapaty, S., Sakr, R. A., Giri, D., Patil, S., Heguy, A., Morrow, M., Modi, S., Norton, L., Rosen, N., Hudis, C., & King, T. A. (2012). Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. *Clinical Cancer Research*, 18(24), 6784–6791. <https://doi.org/10.1158/1078-0432.CCR-12-1785>
- Chen, J., Li, L., Su, J., Li, B., Chen, T., & Wong, Y.-S. (2014). Synergistic apoptosis-inducing effects on A375 human melanoma cells of natural borneol and curcumin. *PloS One*, 9(6), e101277. PubMed. <https://doi.org/10.1371/journal.pone.0101277>
- Chen, J., Wei, Y., Yang, W., Huang, Q., Chen, Y., Zeng, K., & Chen, J. (2022). IL-6: The Link Between Inflammation, Immunity and Breast Cancer. *Frontiers in Oncology*, 12, 903800. <https://doi.org/10.3389/fonc.2022.903800>
- Chen, R., Zhao, X., & Hu, K. (2019). 9—Physically open BBB. Dalam H. Gao & X. Gao (Ed.), *Brain Targeted Drug Delivery System* (hlm. 197–217). Academic Press. <https://doi.org/10.1016/B978-0-12-814001-7.00009-3>
- Chin, C.-H., Chen, S.-H., Wu, H.-H., Ho, C.-W., Ko, M.-T., & Lin, C.-Y. (2014). cytoHubba: Identifying hub objects and sub-networks from complex interactome. *BMC Systems Biology*, 8(4), S11. <https://doi.org/10.1186/1752-0509-8-S4-S11>
- Chung, W.-P., Huang, W.-L., Lee, C.-H., Hsu, H.-P., Huang, W.-L., Liu, Y.-Y., & Su, W.-C. (2022). PI3K inhibitors in trastuzumab-resistant HER2-positive breast cancer cells with PI3K pathway alterations. *American Journal of Cancer Research*, 12(7), 3067–3082.
- Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nature Medicine*, 6(4), 443–446. <https://doi.org/10.1038/74704>
- Daina, A., Michielin, O., & Zoete, V. (2019). SwissTargetPrediction: Updated data and new features for efficient prediction of protein targets of small molecules. *Nucleic Acids Research*, 47(W1), W357–W364. <https://doi.org/10.1093/nar/gkz382>
- de Abreu Pereira, D., Sandim, V., Fernandes, T. F. B., Almeida, V. H., Rocha, M. R., do Amaral, R. J. F. C., Rossi, M. I. D., Kalume, D. E., & Zingali, R. B. (2022). Proteomic Analysis of HCC-1954 and MCF-7 Cell Lines Highlights Crosstalk between αv and $\beta 1$ Integrins, E-Cadherin and HER-2. *International Journal of Molecular Sciences*, 23(17), Article 17. <https://doi.org/10.3390/ijms231710194>
- Doncheva, N. T., Morris, J. H., Gorodkin, J., & Jensen, L. J. (2019). Cytoscape StringApp: Network Analysis and Visualization of Proteomics Data. *Journal of Proteome Research*, 18(2), 623–632. <https://doi.org/10.1021/acs.jproteome.8b00702>
- Dwivedi, S., Purohit, P., Misra, R., Lingeswaran, M., Vishnoi, J. R., Pareek, P., Sharma, P., & Misra, S. (2019). Chapter 5—Application of Single-Cell

- Omics in Breast Cancer. Dalam D. Barh & V. Azevedo (Ed.), *Single-Cell Omics* (hlm. 69–103). Academic Press. <https://doi.org/10.1016/B978-0-12-817532-3.00005-0>
- Filippi, I., Carraro, F., & Naldini, A. (2015). Interleukin-1 β Affects MDAMB231 Breast Cancer Cell Migration under Hypoxia: Role of HIF-1 α and NF κ B Transcription Factors. *Mediators of Inflammation*, 2015, 789414. <https://doi.org/10.1155/2015/789414>
- Gajria, D., & Chandarlapaty, S. (2011). HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. *Expert Review of Anticancer Therapy*, 11(2), 263–275. <https://doi.org/10.1586/era.10.226>
- Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., Cerami, E., Sander, C., & Schultz, N. (2013). Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. *Science signaling*, 6(269), p11. <https://doi.org/10.1126/scisignal.2004088>
- Gilson, M. K., Liu, T., Baitaluk, M., Nicola, G., Hwang, L., & Chong, J. (2016). BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. *Nucleic Acids Research*, 44(D1), D1045–D1053. <https://doi.org/10.1093/nar/gkv1072>
- Gstraunthaler, G., Lindl, T., & van der Valk, J. (2013). A plea to reduce or replace fetal bovine serum in cell culture media. *Cytotechnology*, 65(5), 791–793. <https://doi.org/10.1007/s10616-013-9633-8>
- Harbeck, N., & Gnant, M. (2017). Breast cancer. *The Lancet*, 389(10074), 1134–1150. [https://doi.org/10.1016/S0140-6736\(16\)31891-8](https://doi.org/10.1016/S0140-6736(16)31891-8)
- He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021). Targeting PI3K/Akt signal transduction for cancer therapy. *Signal Transduction and Targeted Therapy*, 6(1), Article 1. <https://doi.org/10.1038/s41392-021-00828-5>
- Heberle, H., Meirelles, G. V., da Silva, F. R., Telles, G. P., & Minghim, R. (2015). InteractiVenn: A web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics*, 16(1), 169. <https://doi.org/10.1186/s12859-015-0611-3>
- Hermawan, A., Putri, H., & Utomo, R. Y. (2020). Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance. *Molecular Diversity*, 24(4), 933–947. <https://doi.org/10.1007/s11030-019-10003-2>
- Hermawan, A., Wagner, E., & Roidl, A. (2016). Consecutive salinomycin treatment reduces doxorubicin resistance of breast tumor cells by diminishing drug efflux pump expression and activity. *Oncology Reports*, 35(3), 1732–1740. <https://doi.org/10.3892/or.2015.4509>
- Hermawan, A., Wulandari, F., Hanif, N., Utomo, R. Y., Jenie, R. I., Ikawati, M., & Tafrihani, A. S. (2022). Identification of potential targets of the

- curcumin analog CCA-1.1 for glioblastoma treatment: Integrated computational analysis and in vitro study. *Scientific Reports*, 12(1), 13928. <https://doi.org/10.1038/s41598-022-18348-9>
- Hosseinzadeh, A., Merikhian, P., Naseri, N., Eisavand, M. R., & Farahmand, L. (2022). MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy. *Cancer Cell International*, 22(1), 110. <https://doi.org/10.1186/s12935-022-02523-z>
- Hur, J., Pak, S. C., Koo, B.-S., & Jeon, S. (2013). Borneol alleviates oxidative stress via upregulation of Nrf2 and Bcl-2 in SH-SY5Y cells. *Pharmaceutical Biology*, 51(1), 30–35. <https://doi.org/10.3109/13880209.2012.700718>
- Jackisch, C. (2006). HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy. *The Oncologist*, 11(S1), 34–41. <https://doi.org/10.1634/theoncologist.11-90001-34>
- Kaewlert, W., Sakonsinsiri, C., Namwat, N., Sawanyawisuth, K., Ungarreevittaya, P., Khuntikeo, N., Armartmuntree, N., & Thanan, R. (2018). The Importance of CYP19A1 in Estrogen Receptor-Positive Cholangiocarcinoma. *Hormones and Cancer*, 9(6), 408–419. <https://doi.org/10.1007/s12672-018-0349-2>
- Kamiloglu, S., Sari, G., Ozdal, T., & Capanoglu, E. (2020). *Guidelines for cell viability assays—Kamiloglu—2020—Food Frontiers—Wiley Online Library*. <https://onlinelibrary.wiley.com/doi/full/10.1002/fft2.44>
- Keiser, M. J., & Hert, J. (2009). Off-Target Networks Derived from Ligand Set Similarity. Dalam E. Jacoby (Ed.), *Chemogenomics: Methods and Applications* (hlm. 195–205). Humana Press. https://doi.org/10.1007/978-1-60761-274-2_8
- Kim, S., Song, J., Park, S., Ham, S., Paek, K., Kang, M., Chae, Y., Seo, H., Kim, H.-C., & Flores, M. (2017). Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar. *mAbs*, 9(4), 704–714. <https://doi.org/10.1080/19420862.2017.1305530>
- Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., Shoemaker, B. A., Wang, J., Yu, B., Zhang, J., & Bryant, S. H. (2016). PubChem Substance and Compound databases. *Nucleic Acids Research*, 44(D1), D1202–D1213. <https://doi.org/10.1093/nar/gkv951>
- Kopp, F., Hermawan, A., Oak, P. S., Ulaganathan, V. K., Herrmann, A., Elnikhely, N., Thakur, C., Xiao, Z., Knyazev, P., Ataseven, B., Savai, R., Wagner, E., & Roidl, A. (2014). Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells. *Translational Oncology*, 7(6), 702–711. <https://doi.org/10.1016/j.tranon.2014.09.002>
- Kreutzfeldt, J., Rozeboom, B., Dey, N., & De, P. (2020). The trastuzumab era: Current and upcoming targeted HER2+ breast cancer therapies. *American Journal of Cancer Research*, 10(4), 1045–1067.

- Kulkarni, M., Sawant, N., Kolapkar, A., Huprikar, A., & Desai, N. (2021). Borneol: A Promising Monoterpenoid in Enhancing Drug Delivery Across Various Physiological Barriers. *AAPS PharmSciTech*, 22(4), 145. <https://doi.org/10.1208/s12249-021-01999-8>
- Kumar, P., Nagarajan, A., & Uchil, P. D. (2018). Analysis of Cell Viability by the MTT Assay. *Cold Spring Harbor Protocols*, 2018(6), pdb.prot095505. <https://doi.org/10.1101/pdb.prot095505>
- Kumar, R., Gupta, M., & Sarwat, M. (2022). Bioinformatics in Drug Design and Delivery. Dalam V. A. Saharan (Ed.), *Computer Aided Pharmaceuticals and Drug Delivery: An Application Guide for Students and Researchers of Pharmaceutical Sciences* (hlm. 641–664). Springer Nature Singapore. https://doi.org/10.1007/978-981-16-5180-9_21
- Lai, H., Liu, C., Hou, L., Lin, W., Chen, T., & Hong, A. (2020). TRPM8-regulated calcium mobilization plays a critical role in synergistic chemosensitization of Borneol on Doxorubicin. *Theranostics*, 10(22), 10154–10170. <https://doi.org/10.7150/thno.45861>
- Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., & Zhang, B. (2019). WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. *Nucleic Acids Research*, 47(W1), W199–W205. <https://doi.org/10.1093/nar/gkz401>
- Liu, W.-J., Yin, Y.-B., Sun, J.-Y., Feng, S., Ma, J.-K., Fu, X.-Y., Hou, Y.-J., Yang, M.-F., Sun, B.-L., & Fan, C.-D. (2018). Natural borneol is a novel chemosensitizer that enhances temozolomide-induced anticancer efficiency against human glioma by triggering mitochondrial dysfunction and reactive oxide species-mediated oxidative damage. *OncoTargets and Therapy*, 11, 5429–5439. <https://doi.org/10.2147/OTT.S174498>
- Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019). PTEN Tumor-Suppressor: The Dam of Stemness in Cancer. *Cancers*, 11(8). <https://doi.org/10.3390/cancers11081076>
- Luque-Cabal, M., García-Tejido, P., Fernández-Pérez, Y., Sánchez-Lorenzo, L., & Palacio-Vázquez, I. (2016). Mechanisms behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. *Clinical Medicine Insights: Oncology*, 10s1, CMO.S34537. <https://doi.org/10.4137/CMO.S34537>
- Maadi, H., Soheilifar, M. H., Choi, W.-S., Moshtaghian, A., & Wang, Z. (2021). Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. *Cancers*, 13(14). <https://doi.org/10.3390/cancers13143540>
- Meng, X., Dong, X., Wang, W., Yang, L., Zhang, X., Li, Y., Chen, T., Ma, H., Qi, D., & Su, J. (2018). Natural Borneol Enhances Paclitaxel-Induced Apoptosis of ESCC Cells by Inactivation of the PI3K/AKT. *Journal of Food Science*, 83(5), 1436–1443. <https://doi.org/10.1111/1750-3841.14143>
- Mercogliano, M. F., De Martino, M., Venturutti, L., Rivas, M. A., Proietti, C. J., Inurriagarro, G., Frahm, I., Allemand, D. H., Deza, E. G., Ares, S.,

- Gercovich, F. G., Guzmán, P., Roa, J. C., Elizalde, P. V., & Schillaci, R. (2017). TNF α -Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. *Clinical Cancer Research*, 23(3), 636–648. <https://doi.org/10.1158/1078-0432.CCR-16-0970>
- Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2021). PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. *International Journal of Molecular Sciences*, 22(1). <https://doi.org/10.3390/ijms22010173>
- Mitri, Z., Constantine, T., & O'Regan, R. (2012). The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy. *Chemotherapy Research and Practice*, 2012, 743193. <https://doi.org/10.1155/2012/743193>
- Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell*, 6(2), 117–127. <https://doi.org/10.1016/j.ccr.2004.06.022>
- Nesset, K. A., Perri, A. M., & Mueller, C. R. (2014). Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors. *Epigenetics*, 9(6), 851–859. <https://doi.org/10.4161/epi.28484>
- Newton, A. C., & Trotman, L. C. (2014). Turning Off AKT: PHLPP as a Drug Target. *Annual review of pharmacology and toxicology*, 54, 537–558. <https://doi.org/10.1146/annurev-pharmtox-011112-140338>
- Piñero, J., Ramírez-Anguita, J. M., Saüch-Pitarch, J., Ronzano, F., Centeno, E., Sanz, F., & Furlong, L. I. (2020). The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids Research*, 48(D1), D845–D855. <https://doi.org/10.1093/nar/gkz1021>
- Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009). Resistance to Trastuzumab in Breast Cancer. *Clinical Cancer Research*, 15(24), 7479–7491. <https://doi.org/10.1158/1078-0432.CCR-09-0636>
- Pufall, M. A. (2015). Glucocorticoids and Cancer. *Advances in experimental medicine and biology*, 872, 315–333. https://doi.org/10.1007/978-1-4939-2895-8_14
- Rani, U., Singh, M., Saith, A., Jain, S. L., Aggarwal, A., & Aggarwal, S. (2022). Evaluation of Use of RPMI Medium to Preserve Cell Morphology for Pleural/Peritoneal Fluid Cytology. *Journal of Cytology*, 39(1), 26–29. https://doi.org/10.4103/joc.joc_130_21
- Riaz, M., van Jaarsveld, M. T., Hollestelle, A., Prager-van der Smissen, W. J., Heine, A. A., Boersma, A. W., Liu, J., Helmijr, J., Ozturk, B., Smid, M., Wiemer, E. A., Foekens, J. A., & Martens, J. W. (2013). MiRNA expression profiling of 51 human breast cancer cell lines reveals subtype

- and driver mutation-specific miRNAs. *Breast Cancer Research : BCR*, 15(2), R33. <https://doi.org/10.1186/bcr3415>
- Riss, T. L., Moravec, R. A., Niles, A. L., Duellman, S., Benink, H. A., Worzella, T. J., & Minor, L. (2004). Cell Viability Assays. Dalam S. Markossian, A. Grossman, K. Brimacombe, M. Arkin, D. Auld, C. Austin, J. Baell, T. D. Y. Chung, N. P. Coussens, J. L. Dahlin, V. Devanarayan, T. L. Foley, M. Glicksman, K. Gorshkov, J. V. Haas, M. D. Hall, S. Hoare, J. Inglese, P. W. Iversen, ... X. Xu (Ed.), *Assay Guidance Manual*. Eli Lilly & Company and the National Center for Advancing Translational Sciences. <http://www.ncbi.nlm.nih.gov/books/NBK144065/>
- Ryu, A. H., Eckalbar, W. L., Kreimer, A., Yosef, N., & Ahituv, N. (2017). Use antibiotics in cell culture with caution: Genome-wide identification of antibiotic-induced changes in gene expression and regulation. *Scientific Reports*, 7(1), Article 1. <https://doi.org/10.1038/s41598-017-07757-w>
- Safari-Alighiarloo, N., Taghizadeh, M., Rezaei-Tavirani, M., Goliaei, B., & Peyvandi, A. A. (2014). Protein-protein interaction networks (PPI) and complex diseases. *Gastroenterology and Hepatology From Bed to Bench*, 7(1), 17–31.
- Schlam, I., Tarantino, P., & Tolaney, S. M. (2022). Overcoming Resistance to HER2-Directed Therapies in Breast Cancer. *Cancers*, 14(16). <https://doi.org/10.3390/cancers14163996>
- Stelzer, G., Rosen, N., Plaschkes, I., Zimmerman, S., Twik, M., Fishilevich, S., Stein, T. I., Nudel, R., Lieder, I., Mazor, Y., Kaplan, S., Dahary, D., Warshawsky, D., Guan-Golan, Y., Kohn, A., Rappaport, N., Safran, M., & Lancet, D. (2016). The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Current Protocols in Bioinformatics*, 54(1), 1.30.1-1.30.33. <https://doi.org/10.1002/cpbi.5>
- Su, J., Lai, H., Chen, J., Li, L., Wong, Y.-S., Chen, T., & Li, X. (2013). Natural borneol, a monoterpenoid compound, potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damage. *PloS One*, 8(5), e63502. <https://doi.org/10.1371/journal.pone.0063502>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Szklarczyk, D., Gable, A. L., Nastou, K. C., Lyon, D., Kirsch, R., Pyysalo, S., Doncheva, N. T., Legeay, M., Fang, T., Bork, P., Jensen, L. J., & von Mering, C. (2021). The STRING database in 2021: Customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Research*, 49(D1), D605–D612. <https://doi.org/10.1093/nar/gkaa1074>

- Tomko, A. M., Whynot, E. G., Ellis, L. D., & Dupré, D. J. (2020). Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. *Cancers*, 12(7), Article 7. <https://doi.org/10.3390/cancers12071985>
- Tortorella, E., Giantulli, S., Sciarra, A., & Silvestri, I. (2023). AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways. *International Journal of Molecular Sciences*, 24(3), 2046. <https://doi.org/10.3390/ijms24032046>
- Triantafyllidi, E., & Triantafillidis, J. K. (2022). Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer. *Biomedicines*, 10(8). <https://doi.org/10.3390/biomedicines10082045>
- Vivekanandhan, S., & Knutson, K. L. (2022). Resistance to Trastuzumab. *Cancers*, 14(20). <https://doi.org/10.3390/cancers14205115>
- Wadji, D. L., Morina, N., Martin-Soelch, C., & Wicky, C. (2023). Methylation of the glucocorticoid receptor gene (NR3C1) in dyads mother-child exposed to intimate partner violence in Cameroon: Association with anxiety symptoms. *PLOS ONE*, 18(4), e0273602. <https://doi.org/10.1371/journal.pone.0273602>
- Wang, M., Ding, L., Zhang, C., Yu, H., Ma, X., Wang, X., Zhong, F., & Zhang, Q. (2023). Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy. *European Journal of Pharmaceutical Sciences*, 181, 106347. <https://doi.org/10.1016/j.ejps.2022.106347>
- Wang, Z., Li, Q., Xia, L., Li, X., Sun, C., Wang, Q., Cai, X., & Yang, G. (2020). Borneol promotes apoptosis of Human Glioma Cells through regulating HIF-1 α expression via mTORC1/eIF4E pathway. *Journal of Cancer*, 11(16), 4810–4822. <https://doi.org/10.7150/jca.45304>
- Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Pelantun, N. S. (2010). Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proceedings of the National Academy of Sciences*, 107(19), 8788–8793. <https://doi.org/10.1073/pnas.1003428107>
- Whittaker, P. A. (2004). The role of bioinformatics in target validation. *Drug Discovery Today: Technologies*, 1(2), 125–133. <https://doi.org/10.1016/j.ddtec.2004.08.002>
- Xia, L., Tan, S., Zhou, Y., Lin, J., Wang, H., Oyang, L., Tian, Y., Liu, L., Su, M., Wang, H., Cao, D., & Liao, Q. (2018). Role of the NF κ B-signaling pathway in cancer. *OncoTargets and therapy*, 11, 2063–2073. <https://doi.org/10.2147/OTT.S161109>
- Xia, X. (2017). Bioinformatics and Drug Discovery. *Current Topics in Medicinal Chemistry*, 17(15), 1709. <https://doi.org/10.2174/1568026617666161116143440>
- Yao, Z.-J., Dong, J., Che, Y.-J., Zhu, M.-F., Wen, M., Wang, N.-N., Wang, S., Lu, A.-P., & Cao, D.-S. (2016). TargetNet: A web service for predicting

potential drug–target interaction profiling via multi-target SAR models. *Journal of Computer-Aided Molecular Design*, 30(5), 413–424. <https://doi.org/10.1007/s10822-016-9915-2>

Yu, Y. F., Wang, Y., Fu, T. P., Chen, K., Liu, J. Q., & Yao, H. R. (2018). Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer. *Breast Cancer Research and Treatment*, 168(2), 337–348. <https://doi.org/10.1007/s10549-017-4592-y>

Zhang, Q.-L., Fu, B. M., & Zhang, Z.-J. (2017). Borneol, a novel agent that improves central nervous system drug delivery by enhancing blood–brain barrier permeability. *Drug Delivery*, 24(1), 1037–1044. <https://doi.org/10.1080/10717544.2017.1346002>